8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 19, 2007

Shire plc

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

England and Wales

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630 98-0484822

(Commission File Number) (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,

Hampshire RG24 8EP England

________________________________________________________________________________

(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code 44 1256 894 000

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

Shire plc has issued the press releases attached as Exhibit 99.01, Exhibit 99.02, Exhibit 99.03, Exhibit 99.04, and Exhibit 99.05 which are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibits are filed herewith:

99.01Press Release dated March 19, 2007

99.02Press Release dated March 22, 2007

99.03Press Release dated March 22, 2007

99.04Press Release dated March 22, 2007

99.05Press Release dated March 22, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ A C Russell
	Name:	Angus Russell
	Title:	Chief Financial Officer

Dated: March 22, 2007

EXHIBIT INDEX
Number	Description
99.01	Press Release dated March 19, 2007
99.02	Press Release dated March 22, 2007
99.03	Press Release dated March 22, 2007
99.04	Press Release dated March 22, 2007
99.05	Press Release dated March 22, 2007

EX-99.1

	EXHIBIT 99.01
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

LIALDA™ (mesalamine)with MMX™ Technology- the First OralOnce-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available

Basingstoke, UK and Philadelphia, PA, US - March 19, 2007 - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) today announced the availability of LIALDA^TM (mesalamine) with MMX^TMTechnology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), a type of inflammatory bowel disease. LIALDA is the first and only FDA-approved once daily oral formulation of mesalamine. The U.S. Food and Drug Administration (FDA) approved LIALDA on January 16, 2007.

LIALDA is available to patients by prescription for oral administration in dosages of 2.4 g/day and 4.8 g/day, allowing patients to take as few as two tablets once daily.Other currently available mesalamines require three to four times daily dosing and six to 16 pills a day. A study found that patients who are not compliant with their mesalamine medications have a five-fold greater risk of disease flares, a serious worsening of symptoms, than compliant patients.

“In clinical trials, LIALDA was superior to placebo in inducing remission. Additionally, LIALDA’s convenient once daily dosing may help address the compliance issues facing so many ulcerative colitis patients,” said Mike Cola, President of Shire's Specialty Pharmaceuticals business. “Shire is pleased to offer this latest advancement in the treatment of ulcerative colitis, which complements our existing GI portfolio and reinforces our commitment to improving the treatment of gastrointestinal diseases.”

"Although not everyone's experience is the same, taking the pills for my disease seemed to consume my life - my next dosage was constantly on my mind," said Becky Pace, a LIALDA clinical trial patient. "I could not believe taking medication once a day would help as much as it did. LIALDA brought my disease into remission."

About LIALDA

LIALDA is part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA). 5-ASA is a well-established drug of choice and often a first-line treatment for UC. LIALDA is indicated for the induction of remission in patients with active, mild to moderate UC. LIALDA is the first new formulation in this class to be approved since 2000. The safety and efficacy of LIALDA has been established for up to eight weeks. LIALDA is the only ulcerative colitis treatment that utilizes MMX Technology. LIALDA with MMX Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic excipients. 

1

Shire has licensed from Giuliani SpA the exclusive rights to develop and commercialize LIALDA in the U.S., Canada, Europe -- known as MEZAVANT™ -- (excluding Italy) and the Pacific Rim. Giuliani SpA retains the development and commercialization rights in Italy.Cosmo Pharmaceuticals SpA, Milan, developed the MMX technology.

LIALDA Effectively Induces Remission

The approval of LIALDA was based on the results of two Phase III clinical studies. The first study assessed the efficacy and safety of LIALDA2.4 g/day given in divided doses twice daily and 4.8 g/day given once daily against placebo in 262 patients. At eight weeks, both doses demonstrated superiority over placebo in the induction of remission (34.1 percent with 2.4 g/day, 29.2 percent with 4.8 g/day, and 12.9 percent with placebo).These study results were recently published in the January 2007 issue of Clinical Gastroenterology and Hepatology.

The second study assessed the efficacy and safety of LIALDA 2.4g/day and 4.8g/day (both given once daily) against placebo in 255 patients. At eight weeks, both once daily doses demonstrated superiority over placebo in the induction of remission (40.5 percent with 2.4 g/day, 41.2 percent with 4.8 g/day, and 22.1 percent with placebo). These study results were published in the January 2007 issue of Gastroenterology.

Important Safety Information

LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond eight weeks have not been established.

LIALDA is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of LIALDA. Caution should be exercised when treating patients with pyloric stenosis or those allergic to sulfasalazine. Mesalamine has been associated with an acute intolerance syndrome (three percent of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to distinguish from a flare of inflammatory bowel disease. Symptoms include cramping, acute abdominal pain and bloody diarrhea, and sometimes fever, headache and rash. If acute intolerance syndrome is suspected, prompt withdrawal is required. Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported. Reports of renal impairment have been associated with mesalamine medications. Caution should be exercised, and LIALDA should be used only if the benefits outweigh the risks. No information is available for patients with hepatic impairment; therefore caution is recommended.

LIALDA is generally well tolerated. The majority of adverse events in the double-blind, placebo-controlled trials were mild or moderate in severity. In clinical trials (N=535), the most common treatment-related adverse events with LIALDA 2.4g/day, 4.8g/day and placebo were headache (5.6 percent, 3.4 percent and 0.6 percent, respectively) and flatulence (four percent, 2.8 percent and 2.8 percent, respectively).Pancreatitis occurred in less than one percent of patients during clinical trials, and resulted in discontinuation of therapy with LIALDA.

About Ulcerative Colitis

Ulcerative colitis is a type of inflammatory bowel disease that produces inflammation and sores or ulcers along the inside of the large intestine, also called the bowel or colon. The sores may interfere with the normal digestive process, often causing cramping, bloating, diarrhea, bleeding, fatigue, weight loss and frequent bowel movements. This serious, chronic autoimmune disease affects approximately 500,000 Americans. For more information on ulcerative colitis, visit www.managinguc.com.

2

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252
Media	Jessica Mann (Rest of the World)	+44 1256 894 280
	Matthew Cabrey (North America)	+1 484 595 8248

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

GIULIANI SpA

Giuliani SpA, founded in 1889, is a privately owned specialty pharmaceutical company strategically focused in gastroenterology and dermatology. It is currently marketing proprietary products for the treatment and management of ulcerative colitis, Crohn’s disease, food intolerances and dermatological disorders. Giuliani’s R&D pipeline includes new chemical entities and biotechnological products targeted to treat inflammatory and autoimmune diseases.

COSMOPharmaceuticalsSpA

Cosmo is a speciality pharma company that aims to become a global leader in optimised therapies for certain gastrointestinal diseases. The company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as ulcerative colitis and Crohn's disease, and colon infections. Cosmo's most advanced development product is LIALDA™/ MEZAVANT™ a treatment for ulcerative colitis that is licensed globally to Giuliani and Shire Pharmaceuticals. Cosmo's proprietary MMX technology is at the core of the company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. For further information on Cosmo, please visit the Company's website: www.cosmopharmaceuticals.com.

3

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder (ADHD) franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD), SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire's planned acquisition of New River Pharmaceuticals announced February 20, 2007; and other risks and uncertainties detailed from time to time in Shire's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2005.

LIALDA is a trademark of Shire LLC.

MMX is a trademark owned by Cosmo Technologies Ltd, Ireland, a wholly-owned subsidiary of Cosmo Pharmaceuticals SpA. 

4

EX-99.2

	EXHIBIT 99.02

Notification of major interests in shares

22 March 2007

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc

2. Reason for the notification	State Yes/No
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify): Revised due to DTR rules - see Section 13	Yes

3. Full name of person(s) subject to the notification obligation:	FMR Corp
4. Full name of shareholder(s) (if different from 3.):	See attached schedule
5. Date of the transaction (and date on which the threshold is crossed or reached if different):	Revised due to DTR rules
6. Date on which issuer notified:	22 March 2007
7. Threshold(s) that is/are crossed or reached:	N/A
8. Notified details:

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights	% of voting rights

			Direct	Direct	Indirect	Direct	Indirect
GB00B0KQX869	16,231,254	16,231,254			16,231,254		2.92%%

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument Expiration date Exercise/Conversion Period/ Date Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights

Total (A+B)
Number of voting rights	% of voting rights
16,231,254	2.92%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are

effectively held, if applicable:

See attached schedule

Proxy Voting:

10. Name of the proxy holder:	FMR Corp
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A

13. Additional information:	As discussed with the FSA, prior to the implementation of the EU Transparency Directive, we aggregated the interests in the shares of FMR Corp (FMR) and Fidelity International Limited (FIL) together for the purposes of shareholder reporting. According to the new DTR rules we are now reporting the indirect holdings of FMR and FIL separately. A separate notification is being submitted for FIL. Please note these holdings are correct as of close of business 20 March 2007.
14. Contact name:	Sophie Hughes
15. Contact telephone number:	fil-regulatoryreporting@uk.fid-intl.com

(Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276)

Schedule:

Shares Held Nominee Management Company

846,920 173,000 30,380 99,054 19,300 107,400 45,400 64,300 79,300 98,300 10,026,900 4,474,900 36,100 130,000 STATE STREET BANK AND TR CO STATE STREET BANK AND TR CO STATE STREET BANK AND TR CO STATE STREET BANK AND TR CO NORTHERN TRUST LONDON NORTHERN TRUST CO MELLON BANK N.A. MELLON BANK N.A. JPMORGAN CHASE BANK JPMORGAN CHASE BANK JPMORGAN CHASE BANK BROWN BROTHERS HARRIMAN AND CO BANK OF NEW YORK BANK OF NEW YORK FMTC FMRCO FMR FICL FMRCO FMTC FMTC FMRCO FPM FMTC FMRCO FMRCO FMRCO FMTC

FMR Corp is the parent holding company of Fidelity Management and Research Company (FMRCO), investment manager for US mutual funds and Fidelity Management Trust Company (FMTC), a US state chartered bank which acts as trustee or investment manager of various pension and trust accounts.

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

EX-99.3

EXHIBIT 99.03

22 March 2007

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc

2. Reason for the notification	State Yes/No
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify): Revised due to DTR rules - see Section 13	Yes

3. Full name of person(s) subject to the notification obligation:	Fidelity International Limited (FIL)
4. Full name of shareholder(s) (if different from 3.):	See attached schedule
5. Date of the transaction (and date on which the threshold is crossed or reached if different):	Revised due to DTR rules
6. Date on which issuer notified:	22 March 2007
7. Threshold(s) that is/are crossed or reached:	N/A
8. Notified details:

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
			Direct	Direct	Indirect	Direct	Indirect
GB00B0KQX869	29,692,537	29,692,537			29,692,537		5.35%

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument Expiration date Exercise/Conversion Period/ Date Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights

Total (A+B)
Number of voting rights	% of voting rights
29,692,537	5.35%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are

effectively held, if applicable:

See attached schedule

Proxy Voting:

10. Name of the proxy holder:	Fidelity International Limited (FIL)
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A

13. Additional information:	As discussed with the FSA, prior to the implementation of the EU Transparency Directive, we aggregated the interests in the shares of FMR Corp (FMR) and Fidelity International Limited (FIL) together for the purposes of shareholder reporting. According to the new DTR rules we are now reporting the indirect holdings of FMR and FIL separately. A separate notification is being submitted for FILFMR Corp. Please note these holdings are correct as of close of business 20 March 2007.
14. Contact name:	Sophie Hughes
15. Contact:	fil-regulatoryreporting@uk.fid-intl.com

(Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276)

Schedule:

Shares Held	Nominee	Management Company
57,800	STATE STREET HONG KONG	FIA(K)l

44,730 56,200 1,043,797 214,800 65,200 21,900 60,800 108,800 337,100 996,828 11,754,185 3,215,218 1,160,817 14,700 28,000 79,200 8,767,651 134,100 334,546 686,800 509,365 STATE STR BK AND TR CO LNDN (S STATE STR BK AND TR CO LNDN (S NORTHERN TRUST LONDON NORTHERN TRUST LONDON NORTHERN TRUST CO NORDDEUTSCHE LANDERSBANK NOMURA TEST AND BANKING MASTER TRUST BANK OF JAPAN JPMORGAN, BOURNEMOUTH JPMORGAN, BOURNEMOUTH JPMORGAN, BOURNEMOUTH JPMORGAN, BOURNEMOUTH JPMORGAN, BOURNEMOUTH DEXIA PRIVATBANK CHASE MANHTTN BK AG FRNKFRT (S BROWN BROTHERS HARRIMAN AND CO BROWN BROS HARRIMN LTD LUX BNP PARIBAS, PARIS BERMUDA TRUST FAR EAST HK BANK OF NEW YORK EUROPE LDN BANK OF NEW YORK BRUSSELS FPM FIL FPM FIL FIL FIL FIJ FIJ FIL FPM FISL FIL FII FPM FPM FIL FIL FIGEST FIM HK FII FPM

Fidelity International Limited (FIL) is the parent holding company for various direct and indirect subsidiaries, including Fidelity Fund Management Limited (FFML), Fidelity Fund Management Limited (FFML), Fidelity Investment Services Ltd (FISL), Fidelity Gestion (FIGEST), Fidelity Investments Advisory (Korea) Limited (FIAKL), Fidelity Investments Management (Hong Kong) Limited (FIMHK), Fidelity Pension Management (FPM), Fidelity Investments Japan (FLJ) and Fidelity Investments International (FII), investment managers for various non-US investment companies and institutional clients.

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

EX-99.4

EXHIBIT 99.04

22 March 2007

Shire plc (the "Company")

Notification of the Exercise of an Option and Sale of Shares by a Director.

The Company was notified by Mr Angus Russell, Chief Financial Officer, on 21 March 2007, of the exercise in London on the same day, of an option over 114,474 ordinary 5p shares in the capital of the Company at an exercise price of £5.065. Mr Russell chose to use a net settled cashless exercise facility run by the Company which resulted in 60,816 shares being allotted to him. The option over the remaining 53,658 shares lapsed.

The Company was further notified, by Mr Russell, on 21 March 2007, of the sale in London on the same day of 53,316 ordinary 5p shares in the capital of the Company at a price of £10.875. Mr Russell retained 7,500 shares.

Following this transaction Mr Russell’s shareholding in the Company increased to 9,719 ordinary shares, and he retains shares under option and stock appreciation rights in the Company totalling 1,172,488 ordinary shares.

T May

Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

EX-99.5

EXHIBIT 99.05

22 March 2007

Shire plc ("Shire")

Purchase of Shares by Employee Benefit Trust

Shire has been notified that on 22 March 2007, the Shire plc Employee Benefit Trust (the “Trust”) purchased 30,000 Ordinary Shares of Shire plc (“Shares”) at an average price of 1093 pence per Share. This purchase was made pursuant to the Trustee’s irrevocable, non-discretionary programme to purchase Ordinary Shares of Shire plc (“Shares”) and American Depositary Receipts of Shire plc (“ADR’s”) for the benefit of the Trust during the period commencing on 01 March 2007 and ending on 30 June 2007.

All of the employees of Shire plc and its subsidiaries, including the Executive Directors and persons exercising managerial responsibility, are potential beneficiaries of the Trust. The Executive Directors and persons exercising managerial responsibility over Shire are therefore deemed to have an interest in the Shares held by the Trust.

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.